Recently published in Nature Biotechnology (1) by Chambers et al, LSB3i is a combination of five small-molecule pathway inhibitors that significantly improves the conventionally slow and inefficient neuronal differentiation of human ESCs or iPSCs. Under the LSB3i treatment, human ESCs or iPSCs very rapidly differentiate into functional neurons with over 75% efficiency within 10 day of differentiation. The resulting neurons exhibit typical markers and functional properties of human nociceptors, including tetrodotoxin (TTX)-resistant, SCN10A-dependent sodium currents and response to nociceptive stimuli, such as ATP and capsaicin. This convenient, robust, and scalable generation of functional human nociceptors from human ESCs/iPSCs using LSB3i provides a platform for basic research, disease modeling, and drug discovery related to pain studies.
XcessBio’s Neuronal-LSB3i contains two combinations/components: LSB (combination of LDN193189/BMP inhibitor and SB431542/TGFβ inhibitor) and 3i (combination of CHIR99021/GSK3 inhibitor, SU5402/FGF-VEGF-PDGF inhibitor, DAPT/Notch inhibitor).
How to Use:
Reference:
Products are for research use only. Not for human use.
BIOLEAF热搜 BIOLEAF试剂盒 BIOLEAF ELISA BIOLEAF试剂 BIOLEAF品牌 BIOLEAF抗体 BIOLEAF耗材 BIOLEAF小仪器
sitemap 细胞库查询 危险品图标 本公司网站所展示销售的产品仅供科研!
沪公网安备 31011202007338号